Respiratory Syncytial Virus (RSV) : Maternal and Infant protection program

  • RSV maternal vaccination program: A single dose of maternal RSV vaccine Abrysvo® provided to people from 28 weeks of pregnancy to pass immunity to their infant, funded under the National Immunisation Program (NIP), commenced on 3 February 2025.

  • RSV infant immunisation program: A dose of Beyfortus™ monoclonal antibody immunisation, available between 1 April 2025 and 30 September 2025, to eligible infants born during or entering their first RSV season, and infants less than 2 years of age who remain at risk of severe RSV disease through their second RSV season.

RSV maternal protection program (Abrysvo)

RSV vaccines and products by cohort table
Source: Department of Health and Aged Care

RSV infant protection program (Beyfortus)

Clinical guidance

Dashboard

Resources for patients